» Articles » PMID: 8764188

Sensitive Methods to Study Human Apolipoprotein B Metabolism Using Stable Isotope-labeled Amino Acids

Overview
Journal Am J Physiol
Specialty Physiology
Date 1996 Jun 1
PMID 8764188
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of the study was to develop a sensitive method using stable isotope-labeled tracers that would permit the determination of apolipoprotein B (apoB) metabolism in very low-density lipoprotein subfractions (VLDL1, Sf 60-400; VLDL2, Sf 20-60), intermediate-density lipoprotein (IDL, Sf 12-20), and low-density lipoprotein (LDL, Sf 0-12). Six normolipidemic subjects were given trideuterated leucine, and its clearance from plasma and appearance in the four apoB-containing lipoprotein fractions were followed by use of a highly sensitive gas chromatography-mass spectrometry technique in which the m + 3-to-m + 2 ion ratio was selectively monitored. This analytic approach permitted the precise measurement of low enrichments in IDL and LDL and extension of the turnover out to 250-300 h. A compartmental model was developed to derive rate constants from the plasma and apoB enrichment curves. The model was uniquely identifiable once parameter dependencies had been introduced to reduce the number of unknowns. Values were obtained for apoB input into all lipoprotein density intervals, together with rates of interconversion and catabolism; these agreed well with results from radioiodinated tracer experiments. An alternative model structure was also explored in which input occurred only into VLDL1. Altering the protocol of tracer administration (bolus vs. primed constant infusion) and dose (over a 10-fold range) had no influence on the results obtained. The analytic and modeling approach described will permit stable isotopes to be used to elucidate key features of apoB metabolism in normal and pathological states.

Citing Articles

Bariatric surgery improves postprandial VLDL kinetics and restores insulin-mediated regulation of hepatic VLDL production.

Yildirim V, Ter Horst K, Gilijamse P, van Harskamp D, Schierbeek H, Jansen H JCI Insight. 2023; 8(16).

PMID: 37432744 PMC: 10543721. DOI: 10.1172/jci.insight.166905.


ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.

Reeskamp L, Millar J, Wu L, Jansen H, van Harskamp D, Schierbeek H Arterioscler Thromb Vasc Biol. 2021; 41(5):1753-1759.

PMID: 33691480 PMC: 8057526. DOI: 10.1161/ATVBAHA.120.315204.


The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.

Bouter K, van Bommel E, Jansen H, van Harskamp D, Schierbeek H, Ackermans M Diabetes Obes Metab. 2020; 22(6):988-996.

PMID: 32026592 PMC: 7318266. DOI: 10.1111/dom.13990.


Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models.

Berglund M, Adiels M, Taskinen M, Boren J, Wennberg B PLoS One. 2015; 10(9):e0138538.

PMID: 26422201 PMC: 4589417. DOI: 10.1371/journal.pone.0138538.


A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model.

Krengel A, Hauth J, Taskinen M, Adiels M, Jirstrand M BMC Syst Biol. 2013; 7:8.

PMID: 23331521 PMC: 3848953. DOI: 10.1186/1752-0509-7-8.